Hepregen company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

hepregen.com

Founded Year

2007

Stage

Merger | Merged

Total Raised

$6.81M

About Hepregen

Hepregen, a spinout of MIT, is developing a platform to reduce the liver toxicity caused by approved drugs. The platform is based on technology developed by Sangeeta Bhatia, an associate professor in the Harvard-MIT Division of Health Sciences and Technology (HST) and MIT's Department of Electrical Engineering and Computer Science. The technology is based on engineered "miniature micro liver cells."

Hepregen Headquarter Location

200 Boston Ave Suite 150

Medford, Massachusetts, 02155,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Hepregen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hepregen is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Hepregen Patents

Hepregen has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/26/2016

6/30/2020

Clusters of differentiation, Transcription factors, Cell biology, Human cells, Immunology

Grant

Application Date

1/26/2016

Grant Date

6/30/2020

Title

Related Topics

Clusters of differentiation, Transcription factors, Cell biology, Human cells, Immunology

Status

Grant

Latest Hepregen News

Hepregen Corporation (Ascendance Biotechnology)

Jun 24, 2020

MIT Deshpande Center 2008 | Healthcare Hepregen Corporation is developing bioengineered solutions for drug development, including a platform for advanced toxicity screening and drug discovery. With its high fidelity model of the human liver, Hepregen's bioengineered solution may provide improved predictivity of how drugs will affect the liver once in humans. For the story of the Deshpande Center project that became Hepregen Corporation, see Case Studies . This company is a spinout of the 2006 project , Human liver models for faster, safer drug development.

  • When was Hepregen founded?

    Hepregen was founded in 2007.

  • Where is Hepregen's headquarters?

    Hepregen's headquarters is located at 200 Boston Ave, Medford.

  • What is Hepregen's latest funding round?

    Hepregen's latest funding round is Merger.

  • How much did Hepregen raise?

    Hepregen raised a total of $6.81M.

  • Who are the investors of Hepregen?

    Investors of Hepregen include Ascendance Biotechnology, National Science Foundation, Massachusetts Life Sciences Center, U.S. Department of Health and Human Services, Battelle Ventures and 4 more.

  • Who are Hepregen's competitors?

    Competitors of Hepregen include Carmot Therapeutics, BioNano Genomics, Echelon Biosciences, Achaogen, Guava Technologies and 12 more.

You May Also Like

A
AureoGen

AureoGen is a research-based biotech company with a focus on discovery and production of commercially and clinically important cyclic peptide-based drugs, through genetic engineering of cyclic peptide producing organisms (as an alternative to complex and expensive synthetic chemistry methods). AureoGen's business is centered on generating intellectual property, both through discovery of genes, molecules and organisms and through development of technology and engineered organisms.

A
AC PharmaChem

AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.

DiscoveryBioMed Logo
DiscoveryBioMed

DiscoveryBioMed (DBM) is a life sciences and biotechnology company. DiscoveryBioMed's mission is to fill a critical niche within the drug discovery industry by specializing in custom human cell engineering and human cell-based drug discovery. Its R&D infrastructure and know-how are leveraged as a CRO service to support the commercial and academic drug discovery community by integrating human cell platforms at any and all points within the drug discovery critical path, from HTS assay development and optimization to lead prioritization and progression, with the end product being 'high value' clinical candidates.

S
Sword Diagnostics

Sword Diagnostics is a life sciences company created in response to the needs of the research, pharmaceutical, and clinical communities. Although researchers are discovering thousands of biomarkers associated with both healthy and diseased-related biological processes, today's life science tools are unable to effectively measure, quantify, and determine the ultimate value of these biological markers. Sword Diagnostics' technology is directly aimed at making it easier to understand these newly emerging biomarkers, as well as extending the utility of existing diagnostics assays. Sword's mission is to provide the next-generation detection technology to life scientists, enabling them to continue advances in medical research, drug discovery and the provision of health care products and services.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

C
Carmot Therapeutics

Carmot Therapeutics is applying its technology, Chemotype Evolution, to address unmet chemical needs in drug discovery, focusing on high-profile targets for which drug leads have been difficult to identify. Carmot has built and optimized this platform to rapidly and efficiently unlock therapeutic target space not currently accessible to conventional small molecule technologies. Carmot is currently using Chemotype Evolution to discover novel drug candidates targeting validated pathways in metabolic disease, oncology and inflammation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.